BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XmAb819 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of XmAb819\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05433142-10849@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:XmAb819: Phase 1 readout est. (NCT05433142)
DESCRIPTION:XmAb819\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStudy: St
 udy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
 \nEstimated primary completion: February 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xmab819#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05433142
URL:https://assetmemo.bio/drug/xmab819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
